Research view
Switch to patient viewGroups that published on this disease or run trials on it, from public registries and publications. Researchers appear by name only once their profile is published.
One card per institution. Pick a target or a country to narrow the list.
The University of Texas MD Anderson Cancer Center · Houston, United States
Is this your team? Claim it
Latest publication · JMIR Cancer, Mar 2026Quality, Empathy, and Readability of AI Chatbot Responses to the Survivorship Needs of Adolescents and Young Adults With Melanoma: Evaluation Study.
University of Pennsylvania · Philadelphia, United States
Is this your team? Claim it
Latest publication · Proc Natl Acad Sci U S A, Dec 2025Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy.
Atlanta, United States
Publications on this disease23
Milan, Italy
Publications on this disease22
Nashville, United States
Publications on this disease14
Erlangen, Germany
Publications on this disease12
6 of 6+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.
Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.
NIH NICHD · R43
Development of a PET Imaging Platform to De-Risk AAV Gene Therapy Clinical Trials
NIH NCI · R44
NIH NCI · R43
Novel Non-Mutagenic Ribosome Biogenesis Inhibitors for the Treatment of Small Cell Lung Cancer
NIH NCI · R01
High-Performance Next-Generation SPECT-CT (NxSPECT) for Theranostics
NIH NIBIB · U24
Medical Imaging and Data Resource Center (MIDRC) – Expansion to Theranostics
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-GF
Continuous Estrogen Monitoring Patch (EstroPatch)
The disease is named only in the funder's project summary, not in the title.
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-PF-EF
European Commission (Horizon Europe) · HORIZON-TMA-MSCA-DN
European Commission (Horizon Europe) · HORIZON-RIA
SCALING OFFSHORE WIND WHILE IMPROVING THE OCEAN THROUGH NET POSITIVE IMPACTS (WINDWIN)
European Commission (Horizon Europe) · HORIZON-IA
NEXT-GEN URBAN FREIGHT LOGISTICS FOR NET ZERO EMISSIONS THROUGH INNOVATIVE SOLUTIONS (NEXTLOGIC)
10 of 194 running projects, newest first. Listed amounts together: US$116.1m + €37.2m.
Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.
Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.
Terminated
Open-Label Surufatinib in European Patients With NET
“Sponsor decision”Registry text, quoted unchanged. SourceTerminated
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
“Study terminated by sponsor”Registry text, quoted unchanged. SourceTrials whose registry record says individual participant data (IPD) will be shared.
No trial in this view states that it shares participant data.
Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.
Capture and Isolation of Circulating Melanoma Cells Using Photoacoustic Flowmetry.
Imaging and Analysis of Melanoma-Secreted Extracellular Vesicles in Tumor-Draining Lymph Nodes.
A Flow Cytometric Assay for Investigating Melanoma Cell Adhesion to Lymphatic Endothelial Cells.
A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells.
Evaluating Melanoma Cell Migration/Invasion in Transwell Assays by Flow Cytometry.
PURE-seq integrates FACS and PIP-seq for single-cell genomics of ultra-rare cells.
See which targets of this disease your abstract mentions, and go to the people working on them.
Matched in your browser only. The text is not sent, saved or logged.
Sources: ClinicalTrials.gov, EU CTR, OpenAlex, PubMed, NIH RePORTER, CORDIS. Machine-matched links are labelled.